Latest news with #Jawa
Time of India
2 days ago
- Business
- Time of India
HUL MD's salary up 3.7% to Rs 23 cr in FY25; number of permanent employees falls 8.4%
New Delhi: HUL Managing Director Rohit Jawa's total remuneration in FY25 has witnessed an increase of 3.75 per cent to Rs 23.23 crore, according to the latest annual report of the FMCG major. Jawa's salary was at Rs 3.65 crore along with allowances of 11.45 crore, a bonus of Rs 3.78 crore and a perquisite - long-term incentives of Rs 2.76 crore. The annual report said that Jawa's remuneration was 146.47 times more than the median remuneration of employees. In FY24, Jawa's remuneration was 153.03 time more than median remuneration of employees. Interestingly, the annual report also highlighted a fall of 8.46 per cent in the total number of permanent employees. According to the report, HUL has 6,604 permanent employees on the rolls of the company as on March 31, 2025. However, a year before HUL had 7,215 permanent employees on the rolls of the company as on March 31, 2024. The percentage increase in the median remuneration of employees for the financial year 2024-25 was 8.39 per cent. "Average increase made in the salaries of employees other than the managerial personnel in the financial year was 4.62 per cent and does not include increase on account of promotions. Increase every year is an outcome of Company's market competitiveness as against its peer group companies as well as financial performance," the report said. Jawa, while addressing the shareholders of the company, said in FY'25 HUL witnessed moderation in urban demand and gradual recovery of rural consumption. "Against this backdrop, we remained focussed on driving volume growth and strengthening competitiveness for the business," he said. While HUL chairman Nitin Paranjpe said the business witnessed a challenging operating environment with uneven weather patterns, volatile commodity prices and muted consumer demand. He further said India is "well-poised to deliver strong and consistent growth with rising affluence, a burgeoning middle class, a vibrant young working population empowered by a strong public digital backbone and growth-oriented policies". "Economic development, technological advancements and a better quality of life have fuelled the aspirations of our consumers. These new dynamics present a significant opportunity for the FMCG sector," he said. The company is witnessing a rapid evolution of the Indian consumer with increased digital penetration and access to information. "We are building a robust portfolio for future growth, by sharpening our 'where to play' choices. In line with this, we announced the acquisition of premium science-backed beauty brand, Minimalist. This acquisition is in line with our vision to become the beauty shapers of India," Paranjpe said. In FY'25, HUL divested its water business, Pureit, and announced the decision to demerge its ice cream business, which consists of brands - Kwality Wall's, Cornetto and Magnum. HUL, which owns popular brands such as Rin, Lux, Surf Excel, Pond's, Dove, Horlicks, Bru, Lipton, etc had a turnover of Rs 60,680 crore and its profit after tax was at Rs 10,644 crore.>
Time of India
3 days ago
- Business
- Time of India
HUL MD Rohit Jawa's salary rises to 23.23 crore in FY25; permanent workforce down 8.4%
Hindustan Unilever Ltd (HUL) Managing Director Rohit Jawa's total remuneration rose by 3.75 per cent in FY25 to 23.23 crore, according to the company's latest annual report. Jawa's annual pay package included a salary of 3.65 crore, allowances of 11.45 crore, a bonus of 3.78 crore, and long-term incentive perquisites amounting to 2.76 crore, PTI reported. The report stated that Jawa's remuneration was 146.47 times more than the median remuneration of employees. In FY24, the ratio was higher at 153.03 times. Meanwhile, the number of permanent employees at the FMCG major fell by 8.46 per cent. HUL had 6,604 permanent employees on its rolls as of March 31, 2025, compared to 7,215 the previous year. The median remuneration of employees increased by 8.39 per cent in FY25. 'Average increase made in the salaries of employees other than the managerial personnel in the financial year was 4.62 per cent and does not include increase on account of promotions. Increase every year is an outcome of the company's market competitiveness as against its peer group companies as well as financial performance,' the annual report noted. Addressing shareholders, Jawa said FY25 saw a moderation in urban demand and a gradual recovery in rural consumption. 'Against this backdrop, we remained focussed on driving volume growth and strengthening competitiveness for the business,' he said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch CFD với công nghệ và tốc độ tốt hơn IC Markets Đăng ký Undo HUL Chairman Nitin Paranjpe said the company navigated a challenging operating environment, marked by uneven weather patterns, volatile commodity prices, and muted consumer demand. He added that India is 'well-poised to deliver strong and consistent growth with rising affluence, a burgeoning middle class, a vibrant young working population empowered by a strong public digital backbone and growth-oriented policies.' 'Economic development, technological advancements and a better quality of life have fuelled the aspirations of our consumers. These new dynamics present a significant opportunity for the FMCG sector,' he said. Paranjpe said HUL is witnessing a rapid evolution of the Indian consumer due to greater digital access and information. 'We are building a robust portfolio for future growth, by sharpening our 'where to play' choices. In line with this, we announced the acquisition of premium science-backed beauty brand, Minimalist. This acquisition is in line with our vision to become the beauty shapers of India,' he said. In FY25, HUL also divested its water business, Pureit, and announced the decision to demerge its ice cream division, which includes brands such as Kwality Wall's, Cornetto and Magnum. The company, which owns brands like Lux, Rin, Surf Excel, Pond's, Dove, Horlicks, Bru, and Lipton, reported a turnover of 60,680 crore and a profit after tax of 10,644 crore in FY25. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
&w=3840&q=100)
Business Standard
3 days ago
- Business
- Business Standard
HUL MD Rohit Jawa's total remuneration rises 3.7% to Rs 23 cr in FY25
HUL Managing Director Rohit Jawa's total remuneration in FY25 has witnessed an increase of 3.75 per cent to Rs 23.23 crore, according to the latest annual report of the FMCG salary was at Rs 3.65 crore along with allowances of 11.45 crore, a bonus of Rs 3.78 crore and a perquisite long-term incentives of Rs 2.76 annual report said that Jawa's remuneration was 146.47 times more than the median remuneration of FY24, Jawa's remuneration was 153.03 time more than median remuneration of employees. ALSO READ: HUL, Kaveri Seeds among 5 stock picks this monsoon; check upside potentialInterestingly, the annual report also highlighted a fall of 8.46 per cent in the total number of permanent to the report, HUL has 6,604 permanent employees on the rolls of the company as on March 31, 2025. However, a year before HUL had 7,215 permanent employees on the rolls of the company as on March 31, percentage increase in the median remuneration of employees for the financial year 2024-25 was 8.39 per cent."Average increase made in the salaries of employees other than the managerial personnel in the financial year was 4.62 per cent and does not include increase on account of promotions. Increase every year is an outcome of Company's market competitiveness as against its peer group companies as well as financial performance," the report while addressing the shareholders of the company, said in FY'25 HUL witnessed moderation in urban demand and gradual recovery of rural consumption."Against this backdrop, we remained focussed on driving volume growth and strengthening competitiveness for the business," he HUL chairman Nitin Paranjpe said the business witnessed a challenging operating environment with uneven weather patterns, volatile commodity prices and muted consumer demand. ALSO READ: Emami, HUL, ITC: Is early monsoon good news for FMCG stocks? Analysts weighHe further said India is "well-poised to deliver strong and consistent growth with rising affluence, a burgeoning middle class, a vibrant young working population empowered by a strong public digital backbone and growth-oriented policies"."Economic development, technological advancements and a better quality of life have fuelled the aspirations of our consumers. These new dynamics present a significant opportunity for the FMCG sector," he company is witnessing a rapid evolution of the Indian consumer with increased digital penetration and access to information."We are building a robust portfolio for future growth, by sharpening our where to play' choices. In line with this, we announced the acquisition of premium science-backed beauty brand, Minimalist. This acquisition is in line with our vision to become the beauty shapers of India," Paranjpe FY'25, HUL divested its water business, Pureit, and announced the decision to demerge its ice cream business, which consists of brands - Kwality Wall's, Cornetto and which owns popular brands such as Rin, Lux, Surf Excel, Pond's, Dove, Horlicks, Bru, Lipton, etc had a turnover of Rs 60,680 crore and its profit after tax was at Rs 10,644 crore.
Yahoo
5 days ago
- Business
- Yahoo
EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
PROVIDENCE, R.I., May 28, 2025 /PRNewswire/ -- EpiVax, Inc., a leader in preclinical immunogenicity assessment for biologic therapeutics and vaccines, is pleased to announce the appointment of Vibha Jawa, PhD, FAAPS as Chief Scientific Officer. Dr. Jawa succeeds EpiVax founder and Executive Chairwoman Annie De Groot, MD, who has transitioned from CSO to Chief Medical Officer. Dr. Jawa brings over two decades of leadership in biologics, vaccine, and gene therapy development and immunogenicity strategy to EpiVax. Most recently, she served as Executive Director of Translational Medicine at Bristol Myers Squibb, where she led bioanalytical strategy, supporting PK- and immunogenicity-related preclinical and clinical assessments across the development pipeline. She has held senior roles at Merck and Amgen where she led immunogenicity assessment efforts, supporting discovery to development. Dr. Jawa has contributed to more than 20 successful IND, BLA, and MAA filings across many therapeutic modalities, and was part of the team at the Institute of Human Gene Therapy (UPENN) that supported the first approved gene therapy product. A recognized thought leader in bioanalysis and immunogenicity from discovery through commercialization, Dr. Jawa has authored over 100 peer-reviewed publications and holds prominent roles in various renowned scientific societies and consortiums, including AAPS, IQ, SC, and EIP. She was named an AAPS fellow in 2022 for her significant contributions. "We're thrilled to welcome Vibha to the team," said Dr. Rich-Henry Schabowsky, CEO of EpiVax. "Her depth of experience in biologics, especially novel modalities, combined with her expertise in evaluating and mitigating immunogenic risk will be instrumental as we continue evolving our methods to meet the complex needs of the industry." Dr. Annie De Groot, EpiVax co-founder and CMO, added: "Dr. Jawa is the perfect scientific leader for EpiVax 2.0: the transformation of our company that began in 2024. She brings the exact energy that EpiVax needs at this juncture. I'm thrilled to be handing the baton to Dr. Jawa, who will ensure that EpiVax remains at the cutting edge of immunogenicity science— pushing boundaries, validating new ideas, building bridges between in vitro data, immunoinformatics and AI, and setting higher standards for translational immunology." Dr. Jawa will have outward and inward facing responsibilities as CSO. She will represent EpiVax at key meetings, while leading internal research and validation efforts. Her leadership will help expand the company's reach into new therapeutic areas and reinforce EpiVax as a trusted partner in biologic and vaccine development. "I'm thrilled to be joining the EpiVax team," said Dr. Jawa. "This is an extraordinary company with a long history of scientific leadership in immunogenicity assessment. I look forward to building on that legacy and continuing to refine the team's approaches, ensuring that we deliver the most accurate, insightful support." About EpiVax: EpiVax is a leader in preclinical immunogenicity assessment and sequence optimization for peptide therapeutics, biologic therapeutics, gene/cell therapies, and vaccines. EpiVax partners with a global roster of companies, agencies, and academics to accelerate immunogenicity risk assessment, immune modulation, and rapid vaccine design. Press Contact:Sarah MonizSmoniz@ View original content: SOURCE EpiVax, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New Indian Express
24-05-2025
- Entertainment
- New Indian Express
The Rise of R Queen – Ragini Dwivedi's boldest role yet
Ragini Dwivedi's most daring avatar in Kannada cinema is set to be showcased in the upcoming film, Jawa, which brings together Rajavardan and Ragini on screen. It also marks Rajavardan's debut production venture under his Barn Swallow Company banner. Directed by Devaa Chakravarthy, Jawa will be made in Kannada, Telugu, and Tamil, and is expected to blend mass appeal with intense storytelling. At the heart of Jawa is R Queen, a character unlike any we've seen on the southern screen—a bold, complex female lead who is commanding in every frame. 'Ragini is not just acting in this film—she becomes R Queen,' says writer-director Devaa. 'She's the face, the force, the phenomenon.' In her first-look poster, revealed on the actor's birthday, Ragini is all steel and grace—adorned in the fierce elegance of Durankara's brand ambassador, a twist and a mythic power to her presence. 'She suits the character like destiny,' says producer Devaa, adding that there is no 'on' and 'off' for Ragini who just owns the screen.
